SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 163 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.68 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,125,480 | -41.2% | 284,124 | -15.3% | 0.02% | -40.0% |
| Q2 2023 | $7,018,813 | +17.5% | 335,347 | +18.5% | 0.04% | 0.0% |
| Q1 2023 | $5,974,489 | -11.3% | 282,883 | +6.8% | 0.04% | -28.6% |
| Q4 2022 | $6,738,193 | +91.5% | 264,762 | +80.9% | 0.06% | +51.4% |
| Q3 2022 | $3,518,000 | +134.7% | 146,382 | +87.9% | 0.04% | +164.3% |
| Q2 2022 | $1,499,000 | -33.9% | 77,904 | -40.3% | 0.01% | +7.7% |
| Q1 2022 | $2,268,000 | -34.4% | 130,479 | -17.3% | 0.01% | -27.8% |
| Q4 2021 | $3,455,000 | +145.2% | 157,832 | +114.1% | 0.02% | +80.0% |
| Q3 2021 | $1,409,000 | -40.6% | 73,732 | -46.6% | 0.01% | -33.3% |
| Q2 2021 | $2,372,000 | -27.1% | 138,172 | -5.0% | 0.02% | -31.8% |
| Q1 2021 | $3,252,000 | +721.2% | 145,441 | +716.0% | 0.02% | +450.0% |
| Q4 2020 | $396,000 | +1.5% | 17,823 | -32.5% | 0.00% | -20.0% |
| Q3 2020 | $390,000 | – | 26,396 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |